Seroepidemiological survey of Toxoplasma gondii infection in patients with gynecological malignant tumors
10.16250/j.32.1374.2019036
- VernacularTitle:妇科恶性肿瘤患者弓形虫感染血清流行病学调查
- Author:
Xi-Ming QIAN
1
;
Guo-Qiang SHEN
1
;
Xiao-Ming WANG
1
Author Information
1. Wuxi No. 9 People’s Hospital, Wuxi Municipal Orthopedic Hospital, Jiangsu Province, Wuxi 214000, China
- Publication Type:Journal Article
- Keywords:
Toxoplasma gondii;
Gynecological malignant tumor;
Seroepidemiological survey
- From:
Chinese Journal of Schistosomiasis Control
2018;30(6):682-684
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the seroprevalence of Toxoplasma gondii infection in patients with gynecological malignant tumors, so as to provide the evidence for the control of T. gondii infections in the patients with gynecological malignant tumors. Methods A total of 327 patients with gynecological malignant tumors were recruited, and 200 women with normal healthy examinations were served as controls. The serum anti-T. gondii IgG and IgM antibodies were detected by using ELISA, and the seroprevalence was compared between the patients and controls, and among various types of cancers. Results The overall seroprevalence of T. gondii was 26.91% (88/327) in the patients with gynecological malignant tumors, which was significantly higher than that (5.00%) in the healthy volunteers (χ2 = 39.36, P<0.01) . The prevalence of anti-T. gondii IgG antibody in the cancer patients was significantly higher than that in the controls (26.30% vs. 5.00%; χ2 = 37.79, P<0.01), while the prevalence of anti-T. gondii IgM antibody in the cancer patients was not significantly different from that in the controls (0.92% vs. 0; corrected χ2 = 0.58, P > 0.01) . The positive rates of anti-T. gondii IgG antibody were 27.68%, 25.47% and 25.69% in ovarian cancer, cervical cancer, and breast cancer patients respectively, which were all significantly higher than those in the controls (χ2 = 32.35, 27.32 and 28.00; all P values<0.01); however, there was no significant difference among the various types of cancer patients in the positive rates of anti-T. gondii IgG antibody (χ2 = 0.17, P > 0.05) . In addition, the positive rates of anti-T. gondii IgM antibody were 1.79%, 0 and 0.92% in ovarian cancer, cervical cancer and breast cancer patients respectively, which was not significantly different from those in the controls (all P values > 0.05). Conclusions The seroprevalence of T. gondii infection is high in the patients with gynecological malignant tumors. It is suggested that the prevention and control of T. gondii infection should be strengthened in these patients.
